Edition:
United States

Atossa Genetics Inc (ATOS.OQ)

ATOS.OQ on NASDAQ Stock Exchange Capital Market

3.28USD
25 May 2018
Change (% chg)

$0.08 (+2.50%)
Prev Close
$3.20
Open
$3.20
Day's High
$3.35
Day's Low
$3.17
Volume
44,325
Avg. Vol
83,703
52-wk High
$18.96
52-wk Low
$2.64

Chart for

About

Atossa Genetics Inc. is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company's leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has... (more)

Overall

Beta: 2.97
Market Cap(Mil.): $8.49
Shares Outstanding(Mil.): 2.65
Dividend: --
Yield (%): --

Financials

  ATOS.OQ Industry Sector
P/E (TTM): -- 35.62 32.94
EPS (TTM): -11.57 -- --
ROI: -244.35 8.14 12.79
ROE: -320.02 11.61 14.67

BRIEF-Atossa Genetics Receives Positive Interim Safety Review In Phase 1 Topical Endoxifen Dose Escalation Study

* ATOSSA GENETICS RECEIVES POSITIVE INTERIM SAFETY REVIEW FROM INDEPENDENT SAFETY COMMITTEE IN PHASE 1 TOPICAL ENDOXIFEN DOSE ESCALATION STUDY IN MEN

May 15 2018

BRIEF-Atossa Genetics Announces Quarterly Loss Per Share $0.71

* ATOSSA GENETICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

May 14 2018

BRIEF-Intracoastal Capital Reports 5.9 Pct passive Stake In Atossa Genetics Inc, As Of April 23, 2018

* INTRACOASTAL CAPITAL LLC REPORTS 5.9 PERCENT PASSIVE STAKE IN ATOSSA GENETICS INC, AS OF APRIL 23, 2018 - SEC FILING Source text for Eikon: (http://bit.ly/2Ki2uGi) Further company coverage:

Apr 27 2018

BRIEF-Atossa Genetics Receives Positive Interim Review From Independent Safety Committee In Phase 1 Topical Endoxifen Dose Escalation Study In Men

* ATOSSA GENETICS RECEIVES POSITIVE INTERIM REVIEW FROM INDEPENDENT SAFETY COMMITTEE IN PHASE 1 TOPICAL ENDOXIFEN DOSE ESCALATION STUDY IN MEN

Apr 24 2018

BRIEF-Atossa Genetics Announces 1 For 12 Reverse Stock Split

* ATOSSA GENETICS INC - ANNOUNCED A REVERSE SPLIT OF ITS COMMON STOCK AT A RATIO OF 1-FOR-12, EFFECTIVE APRIL 20, 2018 Source text for Eikon: Further company coverage:

Apr 20 2018

BRIEF-Atossa Genetics Announces 2017 Financial Results

* ATOSSA GENETICS ANNOUNCES 2017 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE Source text for Eikon: Further company coverage:

Mar 08 2018

Earnings vs. Estimates